drugset / Trial / NCT01206504
Expanded Access to MGAWN1 in Subjects With Suspected West Nile Neuroinvasive Disease; Suspected West Nile Virus Infection; or Substantial Accidental Exposure
Expanded access
No longer available
MacroGenics
National Institute of Allergy and Infectious Diseases (NIAID) · collab
Summary
This study will test an experimental drug called MGAWN1 for the treatment of West Nile infections.
Timeline
- Start
- —
- Primary completion
- —
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | MGAWN1 | Monoclonal antibody | 30 mg/kg | — |